A5045616412- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Sarcoidosis and Beryllium Toxicity Research
- Systemic Sclerosis and Related Diseases
- Systemic Lupus Erythematosus Research
- Medical Imaging and Pathology Studies
- Radiomics and Machine Learning in Medical Imaging
- Rheumatoid Arthritis Research and Therapies
- Inflammatory Myopathies and Dermatomyositis
- Vasculitis and related conditions
- Advanced X-ray and CT Imaging
- Musculoskeletal synovial abnormalities and treatments
- Atherosclerosis and Cardiovascular Diseases
- Herpesvirus Infections and Treatments
- Pulmonary Hypertension Research and Treatments
- Biosimilars and Bioanalytical Methods
- Reproductive System and Pregnancy
- Pregnancy and Medication Impact
- Drug-Induced Adverse Reactions
University of Bari Aldo Moro
2023-2024
To investigate pregnancy outcomes in women with autoimmune rheumatic diseases (ARD) the Italian prospective cohort study P-RHEUM.it.
Rheumatoid arthritis (RA) patients on JAK inhibitors (JAKi) have an increased HZ risk compared to those biologic DMARDs (bDMARDs). Recently, the Adjuvanted Recombinant Zoster Vaccine (RZV) became available worldwide, showing good effectiveness in with inflammatory arthritis. Nevertheless, direct evidence of immunogenicity such a vaccine JAKi or anti-cellular bDMARDs is still lacking. This prospective study aimed assess RZV and safety RA receiving that are known lead impaired immune response....
Objectives Patients with rheumatoid arthritis (RA) and interstitial lung disease (ILD) have increased mortality compared to the general population factors capable of predicting RA-ILD long-term clinical outcomes are lacking. In oncology, radiomics allows quantification tumour phenotype by analysing characteristics medical images. Using specific software, it is possible segment organs on high-resolution computed tomography (HRCT) images extract many features that may uncover not detected...
The aim of this multicenter retrospective study was to investigate the effectiveness and safety available JAK-inhibitors (JAKi) in patients with rheumatoid arthritis (RA) interstitial lung disease (ILD).We retrospectively analyzed classified RA RA-ILD undergoing JAKi 6 Italian tertiary centers from April 2018 June 2022. We included at least months active therapy one high-resolution chest tomography (HRCT) carried out within 3 start treatment. HRCT then compared most recent before last...
The INBUILD study demonstrated the efficacy of nintedanib in treatment progressive fibrosing interstitial lung disease different to idiopathic pulmonary fibrosis, including rheumatoid arthritis (RA)-related ILD. Nevertheless, prevalence RA-ILD patients that may potentially benefit from remains unknown.The aim present multicentre was investigate and possible associated factors patterns a cross-sectional cohort patients.One hundred thirty-four with diagnosis RA-ILD, who were confirmed at...
<h3>Background:</h3> Pulmonary arterial hypertension (PAH) can complicate systemic sclerosis (SSc), representing the leading cause of death in these patients. According to recent epidemiological evidence, about 10% SSc patients may be affected by PAH [1], with a mortality rate 50% after 3 years from diagnosis [2]. Few and outdated information on SSc-PAH Italian population is available, furthermore it would advisable look at any new prognostic factors for improving outcome....
<h3>Background</h3> Interstitial lung disease (ILD) related to rheumatoid arthritis (RA) significantly impacts on quality of life and survival the patients. Data about prevalence natural history RA-ILD are only partially known mainly based retrospective studies. The recent introduction antifibrotic drugs have allowed for first time opportunity treat ILD in RA patients; fact, INBUILD study demonstrated efficacy nintedanib treatment progressive fibrosing different than idiopathic pulmonary...
<h3>Background</h3> Patients with rheumatoid arthritis (RA) and interstitial lung disease (ILD) have increased mortality compared to the general population factors capable of predicting RA-ILD long-term clinical outcomes are lacking. In oncology, radiomics allows quantification tumour phenotype by analysing characteristics medical images [2]. The hypothesis is that distinctive imaging features between forms may help make a prognosis predict therapeutic response for various conditions, thus...
<h3>Background</h3> The treatment to adopt when (Interstitial Lung Disease)ILD is detected in Rheumatoid Arthritis (RA) patients has always been a matter of debate. management and RA-ILD challenging because there still little information available on this topic, the main literature comes from observational studies. No clinical trials have dedicated however its consideration increasing guidelines. There relatively limited data use JAKi with RA-associated ILD. <h3>Objectives</h3> aim...
<h3>Background</h3> Rituximab (RTX) is indicated for treatment of severe small vessel vasculitides (SVV), namely granulomatosis with polyangiitis (GPA) microscopic (MPA) and cryoglobulinemic vasculitis (CV). Currently available RTX molecules include the originator drug (RTX-Or) two biosimilars, CT-P10 GP2013. SVV are rare only few studies evaluated safety efficacy non-medical switch (NMS) from RTX-Or to <sup>[1,2,3]</sup>. No data about clinical use GP2013 switching strategies between...